Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06416007 · ClinicalTrials.gov registry record · Phase 2

Lattice Radiotherapy for Dose-Escalated Palliation of Bulky Tumors

A Phase 2 study of Cancer and Metastatic Cancer, sponsored by University of Cincinnati.

Recruiting
Registry status
Phase 2
Development phase
37
Enrollment target
1
Study location

NCT06416007: Recruiting Phase 2 study of Cancer and Metastatic Cancer, sponsored by University of Cincinnati.

NCT06416007 is a Phase 2 study of Cancer and Metastatic Cancer that is actively recruiting participants, run by University of Cincinnati. The registered enrollment target is 37 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06416007, a Phase 2 study of Cancer and Metastatic Cancer, is actively recruiting participants, sponsored by University of Cincinnati.

RECRUITING
Registry status
Phase 2
Development phase
37 participants
Enrollment target
1
Study location

Study Summary

The purpose of this research study is to determine if lattice radiation therapy (LRT) will provide better treatment for bulky (large) tumors than current standard of care radiotherapy.

Primary Outcome

To evaluate the efficacy of lattice therapy in patients with bulky tumors, as measured by objective response rate (ORR) at 60 days post-treatment.

Interventions

  • RADIATION Lattice therapy (LRT)

Study Locations (1)

Ohio

  • University of Cincinnati Medical Center - Cincinnati

Trial Details

FieldValue
Enrollment Target 37 participants
Start Date 2024-08-02
Est. Completion 2027-06-01
Phase Phase 2
University of Cincinnati

245 total trials

What NCT06416007 shows while recruiting

NCT06416007 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 37 participants, a relatively small participant target, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower).

The record links to 5 conditions, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which Lattice therapy (LRT) is the first listed.

NCT06416007 reports a single indexed study location in Ohio.

Frequently Asked Questions

What is clinical trial NCT06416007 about?

NCT06416007 is a clinical study titled "Lattice Radiotherapy for Dose-Escalated Palliation of Bulky Tumors". The purpose of this research study is to determine if lattice radiation therapy (LRT) will provide better treatment for bulky (large) tumors than current standard of care radiotherapy.

What is the current status of trial NCT06416007?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 37 participants. The study started on 2024-08-02. Estimated completion is 2027-06-01.

What conditions does trial NCT06416007 study?

This clinical trial studies the following conditions: Cancer, Metastatic Cancer, Locally Advanced Solid Tumor, Locally Advanced, Locally Advanced Carcinoma.

What interventions are being tested in trial NCT06416007?

The interventions under investigation include: Lattice therapy (LRT) (RADIATION).

Who is sponsoring clinical trial NCT06416007?

This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06416007 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06416007's enrollment target sits among peer trials

37 482nd of 615 higher than 132 of 615 other Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02800486 · 37 participants · Phase 2

    Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA

  • NCT03173937 · 37 participants · Phase 1

    Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome

  • NCT03295227 · 37 participants · Phase 1

    Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer

  • NCT03401047 · 37 participants · Early Phase 1

    Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06416007, the US trial registry maintained by the National Library of Medicine. NCT06416007 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.